Myriad Genetics specializes in molecular diagnostic testing, offering genetic screening and analysis to help inform medical decisions in cancer, women’s health, and mental health. Its products are ...

First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over ...

We make no change to our $18.50 fair value estimate for no-moat Myriad Genetics, as third-quarter results landed largely as expected. Overall revenue growth of 14% year over year was driven by ...